USA flag logo/image

An Official Website of the United States Government

RAPID TRANSDERMAL DELIVERY OF OPIOID PAIN MEDICATIONS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61045
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
GM066609
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Altea Therapeutics Corporation
Altea Therapeutics Corporation 2056 Weems Road Tucker, GA 30084
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: RAPID TRANSDERMAL DELIVERY OF OPIOID PAIN MEDICATIONS
Agency: HHS
Contract: 1R43GM066609-01
Award Amount: $105,650.00
 

Abstract:

DESCRIPTION (provided by applicant): The American Medical Association reports that undertreatment of pain is a major problem for cancer patients as well as for other disease conditions. Approximately 50-75% of cancer patients have pain that is undertreated, and 25% die in severe unrelieved pain. Noninvasive pain medication delivery systems are ideally suited to improve the quality of life for those who experience chronic pain. Currently available noninvasive systems are slow, variable, or require frequent dosing. The goal of this project is to demonstrate the capability of a novel thermal microporation method to enable rapid infusion of pain medication through the skin. The microporation method is a noninvasive, painless, needless, patch-based system which creates an array of microscopic openings in the stratum corneum that increases the drug flux significantly compared to drugs delivered through intact skin. Four top opioid candidates for microporation delivery will be evaluated with an in vitro drug delivery model system that involves studying freshly harvested hairless mouse skin to determine optimal formulation and microporation delivery parameters. The opioid candidates to be tested in vitro with the thermal microporation method include morphine, hydromorphone, fentanyl, and alfentanil. A small pilot clinical study will also be performed to determine the feasibility of delivering fentanyl with a commercially available transdermal patch in conjunction with the microporation system.

Principal Investigator:

Alan M. Smith
7702700398
ALAN.SMITH@ALTEATECH.COM

Business Contact:

Jonathan Eppstein
7702700398
JONATHAN@ALTEATECH.COM
Small Business Information at Submission:

ALTEA THERAPEUTICS, INC.
ALTEA THERAPEUTICS, INC. 2056 WEEMS RD TUCKER, GA 30084

EIN/Tax ID: 593538644
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No